Browsing Breast Cancer Research by subject "Cancer Care Facilities"
Now showing items 1-1 of 1
(2016-06)Purpose The PARP inhibitor, Olaparib, is approved for women with BRCA-mutated ovarian cancer. Therefore there is an urgent need to test patients and obtain results in time to influence treatment. Models of BRCA testing, ...